University of Pittsburgh researchers have developed an innovative approach to enhance the effectiveness of adoptive cell therapy for cancer treatment by redirecting glucose metabolism. This method addresses the metabolic stresses that T cells endure during in vitro expansion, which can limit their persistence and function in vivo. By using the drug dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase, the researchers promote mitochondrial health, resulting in more robust antitumor responses. This technology has demonstrated compelling results in both mouse models and human cell cultures, offering a promising pathway to improve the therapeutic outcomes of T cell-based cancer therapies.